News|Articles|December 19, 2024

Mastering Antibody-Drug Conjugates: BIOVECTRA's Approach to ADC and Complex Chemistry Manufacturing

BioPharm International sat down with Jean-François Vincent-Rocan, Director of Complex Chemistry Process Development at BIOVECTRA, to discuss antibody-drug conjugate (ADC) manufacturing. Due to their complex manufacture and supply chain management, JF emphasizes the need for a company that greatly understands the challenges and offers solutions that maintain quality and reliability. He also mentions what advancements are to come in this field and how best to stay ahead of a rapidly growing treatment option.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 30th, 2026

18-Month Room-Temperature Data Support Hyaluronidase-Free Antibody Suspensions, Says Nanoform’s Chris Worrall

In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.

October 30th, 2026

Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma

Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.

3D Rendering of Antibody Drug Conjugate Molecules - ADC - with cytotoxic payload | Image credit: © Alpha Tauri 3D - © Alpha Tauri 3D - stock.adobe.com

October 30th, 2026

Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand

Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.

Close-up of a young man’s face with red, butterfly-shaped patches of rash across both cheeks below the eyes. | Image Credit: © velimir - stock.adobe.com

October 30th, 2026

Leads Biolabs Doses First Lupus Patient With LBL-047, a BDCA2/TACI Bifunctional Fusion Protein

The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.

Brain neurons in lysosomal storage diseases, 3D illustration | Image credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com

October 30th, 2026

BioMarin Licenses Subcutaneous Fabry ERT From GC Biopharma, Hanmi

HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.

Close-up of two prefilled syringes on a light blue surface, one in focus with a clear barrel and exposed needle and a labeled syringe blurred in the background. | Image Credit: © omar - stock.adobe.com

October 30th, 2026

FDA Approves Sun Pharma’s Ilumya for Active Psoriatic Arthritis

The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.

October 29th, 2026

Antibody Manufacturing Costs Have Fallen From $35 to About $12 per Gram, Says IIT Delhi’s Anurag Rathore

In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.

October 29th, 2026

Non-Aqueous Suspensions Could Push Antibody Concentrations Above 400 mg/mL, Says Nanoform’s Chris Worrall

As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.

Mastering Antibody-Drug Conjugates: BIOVECTRA's Approach to ADC and Complex Chemistry Manufacturing

Related to this article

Trending on BioPharm International

Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup

Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial

Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial

Non-Aqueous Suspensions Could Push Antibody Concentrations Above 400 mg/mL, Says Nanoform’s Chris Worrall

The BioPharm Brief: Weight Loss Head-to-Head, Precision Cell Therapy, and Individualized Gene Editing